Natco Pharma Ltd is quoting at Rs 1460.95, up 2.42% on the day as on 12:49 IST on the NSE. The stock is up 72.36% in last one year as compared to a 27.7% jump in NIFTY and a 57.37% jump in the Nifty ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

The U.S. Food and Drug Administration has approved Elanco Animal Health's oral drug to protect dogs against six parasitic ...

Gilead Sciences collaborates with Indian companies to produce affordable generic versions of its HIV prevention therapy, ...

WESTLAKE VILLAGE, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical-stage medical ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

The Nifty Pharma index closed on a negative note on Monday. Shares of Natco Pharma Ltd.(up 3.53 per cent), Glenmark ...

Sensex, Nifty updates on 7 October 2024 - Equity benchmark indices, Sensex and Nifty, extended their losing streak to a sixth ...

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.

Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding ...